Cosmo Pharmaceuticals Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	104.17	266.79	92.78	102.09	65.07
Revenue	104.17	266.79	92.78	102.09	65.07
Revenue Growth (YoY)	-60.95%	187.55%	-9.12%	56.88%	6.77%
Cost of Revenue	53.62	45.36	39.34	40.49	32.98
Gross Profit	50.56	221.43	53.44	61.6	32.1
Selling, General & Admin	26.8	36.28	29.94	19.98	10.52
Research & Development	34.18	39.93	27.3	15.46	11.29
Other Operating Expenses	-3.48	-3.06	-1.92	-1.9	-0.82
Operating Expenses	57.49	73.15	55.32	33.54	21
Operating Income	-6.94	148.28	-1.88	28.06	11.1
Interest Expense	-0.12	-0.05	-8.53	-9.16	-8.99
Interest & Investment Income	4.76	2.27	4.07	2.94	3.06
Earnings From Equity Investments	-	-	-	-	17.75
Currency Exchange Gain (Loss)	-2.58	1.02	-1.36	2.76	2.24
Other Non Operating Income (Expenses)	-0.06	-0.07	-0.12	-0.11	-0.48
EBT Excluding Unusual Items	-4.94	151.45	-7.81	24.49	24.68
Gain (Loss) on Sale of Investments	4.02	1.92	1.33	-0.02	-0.68
Pretax Income	-0.92	153.37	-6.49	24.47	24
Income Tax Expense	2.57	20.18	4.21	6.97	2.33
Earnings From Continuing Operations	-3.49	133.19	-10.7	17.51	21.67
Minority Interest in Earnings	-0.12	0.05	-0.08	-0.28	-0
Net Income	-3.61	133.24	-10.78	17.23	21.67
Net Income to Common	-3.61	133.24	-10.78	17.23	21.67
Net Income Growth	-	-	-	-20.52%	-
Shares Outstanding (Basic)	16	16	16	16	17
Shares Outstanding (Diluted)	16	16	16	16	17
Shares Change (YoY)	-2.73%	1.94%	-1.95%	-2.83%	16.81%
EPS (Basic)	-0.23	8.14	-0.67	1.05	1.29
EPS (Diluted)	-0.23	8.12	-0.67	1.05	1.28
EPS Growth	-	-	-	-18.20%	-
Free Cash Flow	-16.69	157.86	19.36	28.71	7.12
Free Cash Flow Per Share	-1.04	9.62	1.20	1.75	0.42
Dividend Per Share	2.100	2.050	2.000	1.050	0.950
Dividend Growth	2.44%	2.50%	90.48%	10.53%	-
Gross Margin	48.53%	83.00%	57.60%	60.34%	49.32%
Operating Margin	-6.66%	55.58%	-2.02%	27.48%	17.06%
Profit Margin	-3.46%	49.94%	-11.62%	16.87%	33.30%
Free Cash Flow Margin	-16.02%	59.17%	20.87%	28.12%	10.95%
EBITDA	5.06	159.87	9.27	41.17	17.81
EBITDA Margin	4.86%	59.92%	9.99%	40.33%	27.37%
D&A For EBITDA	12	11.59	11.14	13.11	6.71
EBIT	-6.94	148.28	-1.88	28.06	11.1
EBIT Margin	-6.66%	55.58%	-2.02%	27.48%	17.06%
Effective Tax Rate	-	13.15%	-	28.47%	9.71%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.